Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can toddlers get three vaccines at once? new study says yes

NCT ID NCT06442449

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a booster polio vaccine (sIPV) at the same time as MMR and hepatitis A vaccines is safe and works well in toddlers. About 889 healthy children aged 18 to 22 months who had already received their first polio and MMR shots took part. Researchers checked immune responses and side effects 30 days after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sabin strain inactivated poliovirus vaccine (sIPV), measles-mumps-rubella (MMR) vaccine, and inactivated hepatitis A (HepA-I) vaccine
What this could lead to
If successful, this could show that giving these booster vaccines together is safe and effective, simplifying childhood immunization schedules.
What could go wrong
This is a completed Phase 4 trial, so results are already known. The main risk is that co-administration might lower immune response or increase side effects compared to separate shots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

889 people

The number who actually took part.

Started

Aug 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 22 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1) healthy toddlers aged 18 months (+4 months); * (2) completed three doses of sIPV primary immunization; * (3) completed one dose of MMR vaccination; * (4) able to provide proof of vaccination; * (5) able to provide legal proof of identity; * (6) The guardians of the participants were able to understand and agree to sign the informed consent. Exclusion Criteria: * (1) a history of vaccination with a polio-containing vaccine component in addition to three sIPV primary doses, according to the vaccination certificate; * (2) have received a second dose of MMR vaccine or a vaccine containing a vaccine for measles, mumps or rubella, or hepatitis A vaccine (inactivated or attenuated), according to the vaccination certificate; * (3) previous history of polio or measles or mumps or rubella or hepatitis A; * (4) known severe allergy to the vaccine or vaccine components, such as urticaria, dyspnea, angioedema; * (5) severe congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; * (6) with autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, asplenia, functional asplenia, and HIV infection); * (7) abnormal coagulation function (such as coagulation factor deficiency, platelet abnormality), or obvious bleeding, hematoma, or ecchymosis after previous intramuscular injection or venipuncture; * (8) have/have had a serious neurological disease (e.g., encephalopathy, epilepsy, convulsions \[other than febrile convulsions\]) or psychosis, a family history of neurological disease or psychosis; * (9) receiving immunosuppressive or other immunomodulatory therapy, cytotoxic therapy within the past 6 months, or planning to receive such treatment during the trial; * (10) have received an immune globulin or other blood products within the past 6 months or plan to receive such treatment during the trial; * (11) receipt of other investigational vaccines within 30 days before vaccination with the investigational vaccines; * (12) receipt of live attenuated vaccine within 28 days before vaccination with the investigational vaccine; * (13) receipt of subunit or inactivated vaccine within 7 days before vaccination with the investigational vaccine; * (14) acute diseases or acute episodes of chronic diseases within the past 7 days; * (15) Axillary temperature \>37.0℃ if fever occurred before vaccination; * (16) which are unsuitable for participation in the clinical trial as judged by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Poliomyelitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jiangsu Center for Disease Control and Prevention (Jiangsu Institute of Public Health)

    Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.